EP4536831A2 — Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
Assigned to Camp4 Therapeutics Corp · Expires 2025-04-16 · 1y expired
What this patent protects
Described herein are methods of modulating GRN gene transcription using antisense oligonucleotides (ASOs) targeting GRN regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for modulating the levels of GRN gene products, for example, i…
USPTO Abstract
Described herein are methods of modulating GRN gene transcription using antisense oligonucleotides (ASOs) targeting GRN regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for modulating the levels of GRN gene products, for example, increasing expression of progranulin (PGRN), to thereby treat diseases and disorders in a subject.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.